Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “RAD51C Gene Mutation”

14 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 14 of 14 results

Not applicableActive Not RecruitingNCT02760849
What this trial is testing

Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations

Who this might be right for
Deleterious BARD1 Gene MutationDeleterious BRCA1 Gene MutationDeleterious BRCA2 Gene Mutation+11 more
M.D. Anderson Cancer Center 374
Not applicableLooking for participantsNCT05420064
What this trial is testing

An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results

Who this might be right for
BRCA1 MutationPOLD1 Gene MutationCDKN2A Mutation+19 more
Memorial Sloan Kettering Cancer Center 1,000
Testing effectiveness (Phase 2)Active Not RecruitingNCT06033092
What this trial is testing

Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion

Who this might be right for
BRCA MutationPALB2 Gene MutationDuctal Carcinoma in Situ+6 more
European Institute of Oncology 200
Early research (Phase 1)Not Yet RecruitingNCT06614751
What this trial is testing

A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway

Who this might be right for
Solid CancersBRCA MutationHRD Cancer+8 more
Danatlas Pharmaceuticals Co., Ltd 112
Not applicableNot Yet RecruitingNCT06726330
What this trial is testing

Risk-reducing Strategies, Including Fimbriectomy, in Women With a Germline Mutation Predisposing to Ovarian or Pelvic Cancer

Who this might be right for
Tubo-ovarian CarcinomaHigh-grade Serous CarcinomaPrimary Peritoneal Carcinoma Stage III+2 more
Centre Oscar Lambret 1,100
Early research (Phase 1)Looking for participantsNCT05787587
What this trial is testing

PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Who this might be right for
Advanced or Metastatic Solid TumorsBreast CancerOvarian Cancer+6 more
IDEAYA Biosciences 216
Not applicableActive Not RecruitingNCT04009148
What this trial is testing

Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome

Who this might be right for
BRCA-Mutated Ovarian CarcinomaBRIP1 Gene MutationMSH2 A636P+5 more
NYU Langone Health 118
Testing effectiveness (Phase 2)Study completedNCT02401347
What this trial is testing

Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

Who this might be right for
Advanced Breast CancerHER2/Neu NegativeTriple-Negative Breast Cancer
Melinda Telli 21
Not applicableTemporarily pausedNCT02993068
What this trial is testing

Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)

Who this might be right for
BARD1 Gene MutationBRCA1 Gene MutationBRCA2 Gene Mutation+12 more
M.D. Anderson Cancer Center 5,200
Testing effectiveness (Phase 2)Ended earlyNCT04171700
What this trial is testing

Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes

Who this might be right for
Solid Tumor
pharmaand GmbH 83
Testing effectiveness (Phase 2)Study completedNCT02873975
What this trial is testing

LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency

Who this might be right for
Advanced Cancers
Dana-Farber Cancer Institute 27
Not applicableLooking for participantsNCT04294927
What this trial is testing

TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention

Who this might be right for
BRCA1 Gene MutationBRCA2 Gene MutationRAD51C Gene Mutation+3 more
University Medical Center Nijmegen 3,000
Testing effectiveness (Phase 2)Active Not RecruitingNCT05033756
What this trial is testing

Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO

Who this might be right for
Malignant Neoplasm of BreastBreast Cancer
Institut fuer Frauengesundheit 11
Testing effectiveness (Phase 2)Active Not RecruitingNCT04030559
What this trial is testing

Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

Who this might be right for
ATM Gene MutationBRCA1 Gene MutationBRCA2 Gene Mutation+14 more
Marc Dall'Era, MD 11